| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document

Title:Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors
Authors:Zwitter, Matjaž (Author)
Rossi, Antonio (Author)
Di Maio, Massimo (Author)
Pohar Perme, Maja (Author)
Lopes, Gilberto (Author)
Files:.pdf Radiology_and_Oncology_2017_Zwitter_et_al._Selection_of_non-small_cell_lung_cancer_patients_for_intercalated_chemotherapy_and_tyrosine_k.pdf (622,21 KB)
URL http://www.degruyter.com/view/j/raon.2017.51.issue-3/raon-2017-0029/raon-2017-0029.xml
Work type:Scientific work (r2)
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Abstract:Background: When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. Methods: Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson's correlation coefficient and the coefficient of determination, separately for first-line and second-line setting. Results: The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with nonsquamous carcinoma (in first-line setting), proportion of never-smokers (both in first- and second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- and second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR-mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months. Conclusions: Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR-mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted.
Keywords:lung cancer, NSCLC, intercalated treatment, EGFR, tyrosine -kinase inhibitors
Year of publishing:2017
Number of pages:str. 241-251
Numbering:št. 3, Letn. 51
ISSN on article:1318-2099
COBISS_ID:2780283 Link is opened in a new window
DOI:10.1515/raon-2017-0029 Link is opened in a new window
License:CC BY-NC-ND 4.0
This work is available under this license: Creative Commons Attribution Non-Commercial No Derivatives 4.0 International
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
AddThis uses cookies that require your consent. Edit consent...

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and Oncology
Shortened title:Radiol. Oncol.
Publisher:De Gruyter Open
COBISS.SI-ID:32649472 New window

Secondary language

Keywords:pljučni rak, NSCLC, interkalacija, zdravljenje, EGFR, inhibitorji tirozin kinaz


Leave comment

You have to log in to leave a comment.

Comments (0)
0 - 0 / 0
There are no comments!

Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica